Clinical Challenge: Case 1

1988 ◽  
Vol 19 (4) ◽  
pp. 245
Author(s):  
Richard C. Cambre ◽  
Harry L. Wilson
Keyword(s):  
Clinical Challenge

IBD Better Understood, Still a Clinical Challenge

2009 ◽  
Vol 42 (4) ◽  
pp. 22
Author(s):  
NANCY WALSH
Keyword(s):  
Clinical Challenge

scholarly journals Phospholipase A2 inhibitor–loaded micellar nanoparticles attenuate inflammation and mitigate osteoarthritis progression

2021 ◽  
Vol 7 (15) ◽  
pp. eabe6374
Author(s):  
Yulong Wei ◽  
Lesan Yan ◽  
Lijun Luo ◽  
Tao Gui ◽  
Biang Jang ◽  
...  
Keyword(s):  
Clinical Success ◽  
Joint Space ◽  
Therapeutic Agents ◽  
Knee Joints ◽  
Phospholipid Membrane ◽  
Drug Discovery And Development ◽  
Knee Oa ◽  
Clinical Challenge ◽  
Osteoarthritis Progression ◽  
Human And Mouse

Treating osteoarthritis (OA) remains a major clinical challenge. Despite recent advances in drug discovery and development, no disease-modifying drug for knee OA has emerged with any notable clinical success, in part, due to the lack of valid and responsive therapeutic targets and poor drug delivery within knee joints. In this work, we show that the amount of secretory phospholipase A2 (sPLA2) enzyme increases in the articular cartilage in human and mouse OA cartilage tissues. We hypothesize that the inhibition of sPLA2 activity may be an effective treatment strategy for OA. To develop an sPLA2-responsive and nanoparticle (NP)–based interventional platform for OA management, we incorporated an sPLA2 inhibitor (sPLA2i) into the phospholipid membrane of micelles. The engineered sPLA2i-loaded micellar NPs (sPLA2i-NPs) were able to penetrate deep into the cartilage matrix, prolong retention in the joint space, and mitigate OA progression. These findings suggest that sPLA2i-NPs can be promising therapeutic agents for OA treatment.

scholarly journals Engineering multifunctional bactericidal nanofibers for abdominal hernia repair

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Samson Afewerki ◽  
Nicole Bassous ◽  
Samarah Vargas Harb ◽  
Marcus Alexandre F. Corat ◽  
Sushila Maharjan ◽  
...  
Keyword(s):  
Hernia Repair ◽  
Biological Properties ◽  
Abdominal Hernia ◽  
Fabrication Technology ◽  
Tissue Adhesions ◽  
Blood Vessel Formation ◽  
Clinical Challenge ◽  
Engineering Strategy ◽  
Clinical Problems

AbstractThe engineering of multifunctional surgical bactericidal nanofibers with inherent suitable mechanical and biological properties, through facile and cheap fabrication technology, is a great challenge. Moreover, hernia, which is when organ is pushed through an opening in the muscle or adjacent tissue due to damage of tissue structure or function, is a dire clinical challenge that currently needs surgery for recovery. Nevertheless, post-surgical hernia complications, like infection, fibrosis, tissue adhesions, scaffold rejection, inflammation, and recurrence still remain important clinical problems. Herein, through an integrated electrospinning, plasma treatment and direct surface modification strategy, multifunctional bactericidal nanofibers were engineered showing optimal properties for hernia repair. The nanofibers displayed good bactericidal activity, low inflammatory response, good biodegradation, as well as optimal collagen-, stress fiber- and blood vessel formation and associated tissue ingrowth in vivo. The disclosed engineering strategy serves as a prominent platform for the design of other multifunctional materials for various biomedical challenges.

The management of patients with uterine sarcoma: A debated clinical challenge

2008 ◽  
Vol 65 (2) ◽  
pp. 129-142 ◽  
Author(s):  
Angiolo Gadducci ◽  
Stefania Cosio ◽  
Antonella Romanini ◽  
Andrea Riccardo Genazzani
Keyword(s):  
Uterine Sarcoma ◽  
Clinical Challenge

scholarly journals The importance of early detection of endotoxemia

2016 ◽  
Vol 22 (7) ◽  
pp. 503-509 ◽  
Author(s):  
Barbara Adamik ◽  
Jakub Smiechowicz ◽  
Andrzej Kübler
Keyword(s):  
Septic Shock ◽  
Point Of Care ◽  
Point Of Care Testing ◽  
Clinical Challenge ◽  
Endotoxin Activity ◽  
Sepsis And Septic Shock ◽  
Clinical Conditions ◽  
Endotoxin Elimination ◽  
Selection Of Patients ◽  
Selection Of

Endotoxin is considered a key signaling molecule in the pathogenesis of sepsis and septic shock. Anti-endotoxin therapies may result in the improvement of a patient’s clinical condition and lower mortality. The pressing clinical challenge is to identify patients for whom endotoxin elimination would be the most beneficial. An endotoxin activity assay (EAA) has been available for detection of endotoxins, allowing selection of patients at high risk of endotoxemia in intensive care units (ICUs). We studied a cohort of 172 consecutive patients who had septic shock on admission to the ICU. Endotoxin activity (EA) was measured with a rapid chemiluminescent EAA, regarded as point-of-care testing. Endotoxemia with a mean EA of 0.59 ± 0.14 EAU was present in 104 patients (60%) and absent in 68 patients (EA = 0.25 ± 0.11 EAU). The risk of endotoxemia increased with the presence of a Gram-negative infection [odds ratio (OR) 3.1, 95% confidence interval (CI) 1.6–5.9; P = 0.001] and bacteremia (OR 3.8, 95% CI 1.6–8.9; P = 0.02) but did not change with a diagnosis of peritonitis (OR 1.03, 95% CI 0.54–1.97; P = 0.90). These findings indicate that anti-endotoxin interventions should be tailored to individual patients based on both clinical conditions and measured endotoxin levels.

Neuroblastoma — from Genetic Profiles to Clinical Challenge

2005 ◽  
Vol 353 (21) ◽  
pp. 2215-2217 ◽  
Author(s):  
Brian H. Kushner ◽  
Nai-Kong V. Cheung
Keyword(s):  
Clinical Challenge ◽  
Genetic Profiles

scholarly journals Primary Tubercular Chest Wall Abscess in a Young Immunocompetent Male

2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Shweta Sharma ◽  
R. K. Mahajan ◽  
V. P. Myneedu ◽  
B. B. Sharma ◽  
Nandini Duggal
Keyword(s):  
Chest Wall ◽  
Immunocompetent Patient ◽  
Rare Entity ◽  
Hematogenous Spread ◽  
Clinical Challenge ◽  
Chest Wall Abscess ◽  
Direct Inoculation ◽  
Underlying Pathology ◽  
Patient Infection ◽  
Rule Out

Chest wall tuberculosis is a rare entity especially in an immunocompetent patient. Infection may result from direct inoculation of the organisms or hematogenous spread from some underlying pathology. Infected lymph nodes may also transfer the bacilli through lymphatic route. Chest wall tuberculosis may resemble a pyogenic abscess or tumour and entertaining the possibility of tubercular etiology remains a clinical challenge unless there are compelling reasons of suspicion. In tuberculosis endemic countries like India, all the abscesses indolent to routine treatment need investigation to rule out mycobacterial causes. We present here a case of chest wall tuberculosis where infection was localized to skin only and, in the absence of any evidence of specific site, it appears to be a case of primary involvement.

Sign in / Sign up

Export Citation Format

Share Document